These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17552415)

  • 1. [Guideline 'Cardiovascular Risk Management'].
    Burgers JS; Simoons ML; Hoes AW; Stehouwer CD; Stalman WA
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1068-74. PubMed ID: 17552415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bold Promise Project: a system change in primary care to support cardiovascular risk screening.
    Sinclair G; Kerr A
    N Z Med J; 2006 Nov; 119(1245):U2312. PubMed ID: 17146487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support.
    Colvine K; Kerr AJ; McLachlan A; Gow P; Kumar S; Ly J; Wiltshire C; Robinson E; Dalbeth N
    N Z Med J; 2008 Nov; 121(1285):73-81. PubMed ID: 19079439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing cardiovascular disease in women.
    Hayes SN
    Am Fam Physician; 2006 Oct; 74(8):1331-40. PubMed ID: 17087427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.
    Metcalf PA; Wells S; Scragg RK; Jackson R
    N Z Med J; 2008 Sep; 121(1281):49-57. PubMed ID: 18797484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease prevention: the new Joint British Societies' guidelines.
    Laker MF;
    Ann Clin Biochem; 2006 Sep; 43(Pt 5):335-9. PubMed ID: 17022874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study.
    Ferrara A; Mangione CM; Kim C; Marrero DG; Curb D; Stevens M; Selby JV;
    Diabetes Care; 2008 Jan; 31(1):69-74. PubMed ID: 17934157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention for acute coronary syndrome in rural South Australia: are drugs best? What about the rest?
    Wachtel TM; Kucia AM; Greenhill JA
    Rural Remote Health; 2008; 8(4):967. PubMed ID: 18855517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of New Zealand CVD risk chart adjustments for family history and ethnicity on eligibility for treatment (PREDICT CVD-5).
    Wells S; Kerr A; Broad J; Riddell T; Kenealy T; Jackson R
    N Z Med J; 2007 Sep; 120(1261):U2712. PubMed ID: 17853933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CBO guideline 'High blood pressure' (revision)].
    Grobbee DE; Tuut MK; Hoes AW
    Ned Tijdschr Geneeskd; 2001 Oct; 145(43):2071-6. PubMed ID: 11715592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):121-37. PubMed ID: 19287307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of dyslipidaemia - evidence and practical recommendations.
    Nestel PJ; O'Brien R; Nelson M
    Aust Fam Physician; 2008 Jul; 37(7):521-7. PubMed ID: 18592069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular risk reduction: impact of an international project].
    Colle B; Brusaferro S;
    Ann Ig; 2008; 20(3 Suppl 1):43-8. PubMed ID: 18773604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing CVD risk - integration of clinical and laboratory criteria.
    Tognarini DP; Sullivan DR; Thomas DW; Sikaris K
    Aust Fam Physician; 2008 Jun; 37(6):422-7. PubMed ID: 18523695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular protection paradigms: is change on the horizon?
    Papademetriou V
    Rev Cardiovasc Med; 2007; 8(4):200-13. PubMed ID: 18192943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors.
    Marant C; Romon I; Fosse S; Weill A; Simon D; Eschwège E; Varroud-Vial M; Fagot-Campagna A
    Diabetes Metab; 2008 Feb; 34(1):38-45. PubMed ID: 18068386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.